To include your compound in the COVID-19 Resource Center, submit it here.

Cellestis, Qiagen deal

Qiagen will acquire Australian diagnostics company Cellestis for A$3.55 per share or A$341

Read the full 138 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE